Innovus Pharmaceuticals Inc. (fka INNV)

[s_Henderson]

Ok, malpractice might have been the wrong word I chose. Language barrier.

At least in terms of revenue we would be heading into the range you mentioned if FlutiCare was approved soon. I still think his estimate of $15 mio. FlutiCare revs for the first year on the shelves is conservative. Fits his underpromise and overdeliver strategy.
The crucial thing so is that with FDA approval the perception of the stock will change drastically. This will help the share price immensly even if the fundamentals would still be lagging somewhat behind at this stage. I don't think you will have much luck trying to mathematically derive the share price of a pennystock like Innovus at some time point X based on pure fundamentals.